SGS (Belgium)

Recent papers from SGS (Belgium)

1. Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)Blood · 2026
2. Why do healthy volunteers participate in clinical trials?British Journal of Clinical Pharmacology · 2026
3. Unexpected Clinical Drug-Drug Interaction of Fexinidazole on Midazolam Pharmacokinetics: Insights into Underlying Mechanisms from Clinical Phase I Study Results and Supporting In Vivo/Vitro EvidenceClinical Drug Investigation · 2025
4. Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participantsBritish Journal of Clinical Pharmacology · 2025
5. Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humansAntimicrobial Agents and Chemotherapy · 2025
6. Healthy participant engagement in early clinical trials: results from the European EUFEMED surveyFrontiers in Pharmacology · 2025
7. Polyfluoroalkyl substances in dedicated hazardous waste incinerators: Framework and industrial scale experimental estimation of destruction and removal efficiencyWaste Management & Research The Journal for a Sustainable Circular Economy · 2025
8. Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 studyThe Lancet Microbe · 2024
9. LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trialClinical and Translational Science · 2024
10. Mixed-Method Systematic Review and Meta-Analysis of Shared Decision-Making Tools for Cancer ScreeningCancers · 2023
11. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein ReceptorCirculation · 2023
12. Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I studyEBioMedicine · 2022
13. Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection StudyAmerican Journal of Tropical Medicine and Hygiene · 2021
14. A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy SubjectsClinical Pharmacology in Drug Development · 2021
15. Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 StudyThe Journal of Clinical Pharmacology · 2020
16. Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy VolunteersClinical Pharmacology in Drug Development · 2019
17. Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group TrialsRheumatology and Therapy · 2018
18. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studiesBritish Journal of Clinical Pharmacology · 2017
19. A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteersHuman Psychopharmacology Clinical and Experimental · 2017
20. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjectsExpert Opinion on Investigational Drugs · 2016